Swiss National Bank raised its position in shares of AxoGen, Inc Common Stock (NASDAQ:AXGN) by 5.7% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 52,200 shares of the medical equipment provider’s stock after buying an additional 2,800 shares during the quarter. Swiss National Bank’s holdings in AxoGen, Inc Common Stock were worth $2,623,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in AXGN. Wells Fargo & Company MN lifted its position in shares of AxoGen, Inc Common Stock by 64.5% during the first quarter. Wells Fargo & Company MN now owns 711,411 shares of the medical equipment provider’s stock valued at $25,966,000 after buying an additional 278,895 shares during the last quarter. Rhumbline Advisers lifted its position in shares of AxoGen, Inc Common Stock by 5.5% during the first quarter. Rhumbline Advisers now owns 25,538 shares of the medical equipment provider’s stock valued at $932,000 after buying an additional 1,335 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its position in shares of AxoGen, Inc Common Stock by 3.9% during the first quarter. Schwab Charles Investment Management Inc. now owns 147,843 shares of the medical equipment provider’s stock valued at $5,397,000 after buying an additional 5,604 shares during the last quarter. Eagle Asset Management Inc. purchased a new stake in shares of AxoGen, Inc Common Stock during the first quarter valued at about $9,793,000. Finally, Northern Trust Corp lifted its position in shares of AxoGen, Inc Common Stock by 0.5% during the first quarter. Northern Trust Corp now owns 332,844 shares of the medical equipment provider’s stock valued at $12,149,000 after buying an additional 1,649 shares during the last quarter. 82.83% of the stock is owned by institutional investors and hedge funds.

Several research firms have commented on AXGN. BidaskClub lowered shares of AxoGen, Inc Common Stock from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 12th. Leerink Swann reissued an “outperform” rating and set a $70.00 price target on shares of AxoGen, Inc Common Stock in a research report on Tuesday, June 26th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $45.00 price target on shares of AxoGen, Inc Common Stock in a research report on Thursday, August 9th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. AxoGen, Inc Common Stock presently has an average rating of “Buy” and a consensus price target of $44.67.

Shares of AxoGen, Inc Common Stock stock opened at $36.10 on Thursday. The company has a market capitalization of $1.56 billion, a P/E ratio of -116.45 and a beta of -0.28. AxoGen, Inc Common Stock has a 52 week low of $18.05 and a 52 week high of $56.85.

AxoGen, Inc Common Stock (NASDAQ:AXGN) last announced its quarterly earnings data on Wednesday, August 1st. The medical equipment provider reported ($0.09) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.01). The company had revenue of $20.58 million during the quarter, compared to analysts’ expectations of $21.25 million. AxoGen, Inc Common Stock had a negative net margin of 24.96% and a negative return on equity of 26.50%. The business’s revenue for the quarter was up 35.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.04) earnings per share. research analysts anticipate that AxoGen, Inc Common Stock will post -0.61 earnings per share for the current fiscal year.

In related news, Director Amy Mcbride Wendell acquired 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 14th. The stock was purchased at an average cost of $36.89 per share, with a total value of $184,450.00. Following the transaction, the director now directly owns 18,333 shares of the company’s stock, valued at approximately $676,304.37. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 7.86% of the company’s stock.

AxoGen, Inc Common Stock Profile

AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Featured Article: Return on Investment (ROI) Defined, Explained

Want to see what other hedge funds are holding AXGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AxoGen, Inc Common Stock (NASDAQ:AXGN).

Institutional Ownership by Quarter for AxoGen, Inc Common Stock (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Inc Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.